A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 

Slides:



Advertisements
Similar presentations
Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles  Ryan G. Steward,
Advertisements

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
A review and meta-analysis of prospective trials comparing different catheters used for embryo transfer  William M. Buckett, M.D.  Fertility and Sterility 
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Age at menarche: a predictor of diminished ovarian function?
Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates  Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.
Daily physical activity and hot flashes in the Study of Women's Health Across the Nation (SWAN) Flashes Study  Carolyn Gibson, M.P.H., M.S., Karen Matthews,
Karl R. Hansen, M. D. , Ph. D. , George M. Hodnett, M. D
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Michael M. Alper, M.D.  Fertility and Sterility 
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials  Ana Cobo, Ph.D., César Diaz, M.D. 
Dennis J. Hand, Ph. D. , Vanessa L. Short, Ph. D. , M. P. H. , Diane J
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer 
Neohormones as biomarkers of reproductive health
Growth rates of ovarian follicles during natural menstrual cycles, oral contraception cycles, and ovarian stimulation cycles  Angela R. Baerwald, Ph.D.,
Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study  Leonidas Mamas, M.D., Ph.D. 
Effect of the initiation of progesterone supplementation in in vitro fertilization–embryo transfer outcomes: a prospective randomized controlled trial 
Konstantinos Pantos, M. D. , Evangelos Makrakis, M. D
Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D
A comparison of blood spot vs
The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility  Alexander M. Quaas, M.D.,
Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization  Ginny Mounce,
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Oocyte cryopreservation
Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.
Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating.
Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials  Valeria M.S.
Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D
Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study  Ahmet Erdem, M.D., Mehmet Erdem,
Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial  Robert Boostanfar, M.D.,
Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis  Laura P. Smith, M.D.,
Tomer Singer, M. D. , David H. Barad, M. D. , M. S
Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility  Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,
Clomiphene citrate at 50: the dawning of assisted reproduction
Synchronization of ovarian stimulation with follicle wave emergence in patients undergoing in vitro fertilization with a prior suboptimal response: a.
Mohamed Fawzy, M. D. , Mohamed Y. AbdelRahman, M. D. , Mohamed H
Ovarian hyperstimulation secondary to ectopic secretion of follicle-stimulating hormone. Literature review prompted by a case  Jorge Burgos, M.D., Patricia.
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Effect of letrozole at 2. 5 mg or 5
Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.
Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study  Carlo.
Thomas M. D’Hooghe, M. D. , Ph. D. , Bénédicte Denys, M. D
Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,
Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis.
Prospective cohort study of three- versus two-dimensional ultrasound for prediction of oocyte maturity  Doron Shmorgun, M.D., Edward Hughes, M.D., Patrick.
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Effectiveness of highly purified human menopausal gonadotropin vs
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Cabergoline and Ganirelix Therapy for Early Moderate to Severe Ovarian Hyperstimulation Syndrome (OHSS) Results in Faster Recovery than in Early Untreated.
Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Sedigheh Borna, M.D., Azita Nasery, M.D.  Fertility and Sterility 
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
A review and meta-analysis of prospective trials comparing different catheters used for embryo transfer  William M. Buckett, M.D.  Fertility and Sterility 
Fertility and Sterility
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Ronald M. Yang, M. D. , Richard A. Fefferman, M. D. , Charles E
Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function  David H. Barad, M.D., M.S., Andrea Weghofer,
In vitro sildenafil citrate use as a sperm motility stimulant
Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles 
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization  Ginny Mounce,
A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.
Presentation transcript:

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data  Hind T. Hatoum, Ph.D., William R. Keye, M.D., Richard P. Marrs, M.D., Surrey M. Walton, Ph.D., Dennis C. Marshall, R.N., M.S., Ph.D.  Fertility and Sterility  Volume 83, Issue 3, Pages 804-807 (March 2005) DOI: 10.1016/j.fertnstert.2004.08.024 Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

FIGURE 1 Outline of Markov model illustrating transition between health states for each treatment cycle. OHSS = ovarian hyperstimulation syndrome. Fertility and Sterility 2005 83, 804-807DOI: (10.1016/j.fertnstert.2004.08.024) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.